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During year 6 (2005–2006) of the Prospective Resis-
tant Organism Tracking and Epidemiology for the Ketolide 
Telithromycin surveillance study, 6,747 Streptococcus pneu-
moniae isolates were collected at 119 centers. The suscep-
tibility of these isolates to macrolides was compared with 
data from previous years. Macrolide resistance increased 
significantly	in	year	6	(35.3%)	from	the	stable	rate	of	≈30%	
for the previous 3 years (p<0.0001). Macrolide resistance 
increased  in  all  regions  of  the  United  States  and  for  all 
patient age groups. Rates were highest in the south and 
for	children	0–2	years	of	age.	Lower-level	efflux	[mef(A)]–
mediated  macrolide  resistance  decreased  in  prevalence 
to	≈50%,	and	highly	resistant	[erm(B) + mef(A)] strains in-
creased	to	25%.	Telithromycin	and	levofloxacin	susceptibil-
ity	rates	were	>99%	and	>98%,	respectively,	irrespective	of	
genotype. Pneumococcal macrolide resistance in the Unit-
ed	States	showed	its	first	significant	increase	since	2000.	
High-level macrolide resistance is also increasing. 
A
ntimicrobial  drug  treatment  of  community-acquired 
respiratory tract infections (RTIs) is usually initiated 
when the causative pathogen has not been documented. 
Treatment is therefore chosen empirically on the basis of 
potential  pathogens  and  their  antimicrobial  susceptibil-
ity. Streptococcus pneumoniae is the major pathogen re-
sponsible for community-acquired RTIs (1), and treatment 
guidelines advise the use of agents that provide adequate 
coverage of this pathogen (2).
Although  macrolides  such  as  azithromycin  and 
clarithromycin are active against S. pneumoniae and are 
in widespread clinical use, increasing in vitro bacterial re-
sistance may have compromised their use. Resistance to 
macrolides in S. pneumoniae increased steadily during the 
1990s; however, recent surveillance studies indicate that 
resistance may have plateaued at ≈30% in the United States 
(3–5). Although the link between in vitro resistance and 
clinical outcome is not fully understood, recent studies pro-
vide evidence that infection with macrolide-resistant pneu-
mococci is a notable risk factor for failure of macrolide 
therapy in community-acquired RTIs (6–9).
Resistance to macrolides in S. pneumoniae is medi-
ated by 2 major mechanisms: target modification caused 
by  a  ribosomal  methylase  encoded  by  the  erm(B)  gene 
or  drug  efflux  encoded  by  the  mef(A)  gene.  High-level 
macrolide resistance (MIC required to inhibit growth in 
90% of organisms [MIC90] >32 μg/mL) is usually associ-
ated with erm(B), whereas mef(A)-mediated resistance, the 
most prevalent mechanism in the United States (10), usu-
ally results in lower-level resistance (MIC90 1–4 μg/mL) 
(11,12). Results from the Prospective Resistant Organism 
Tracking and Epidemiology for the Ketolide Telithromy-
cin (PROTEKT US) surveillance study, covering isolates 
collected during 2000–2004, indicate that the prevalence 
of mef(A) is decreasing, and isolates harboring erm(B) and 
mef(A) genes are becoming increasingly common (13). In 
addition, isolates carrying only the mef(A) gene showed a 
higher-level resistance (MIC90 = 16 μg/mL) than observed 
previously (10). This analysis reports results from year 6 
of  PROTEKT  US  (2005–2006),  focusing  on  macrolide-
resistance rates and mechanisms in S. pneumoniae isolates 
collected from patients with community-acquired RTIs.
Methods
To reduce bias when interpreting trends, we restricted 
the analysis to S. pneumoniae isolates collected from the 
119 centers that had previously provided isolates for year 5 
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of the study. Isolates were collected from patients in whom 
clinical acute/chronic bacterial sinusitis, acute/chronic oti-
tis media, acute bacterial exacerbations of chronic bron-
chitis, chronic obstructive pulmonary disease, or commu-
nity-acquired pneumonia had been diagnosed. Specimen 
sources included ear, blood, bronchoalveolar lavage, sinus 
aspirate, and sputum. Isolates were included from adults 
and children.
MICs  for  the  antimicrobial  agents  were  determined 
at the Central Microbiology Institute (CMI; Portland, OR, 
USA) by using the Clinical and Laboratory Standards In-
stitute (CLSI) broth microdilution method (14) and were 
interpreted  by  using  CLSI  breakpoints  (15).  The  break-
points  used  for  amoxicillin-clavulanate  were  <2  μg/mL 
(susceptible), 4 μg/mL (intermediate), and >8 μg/mL (re-
sistant). Breakpoints used for cefpodoxime were <0.5 μg/
mL (susceptible), 1 μg/mL (intermediate), and >2 μg/mL 
(resistant). Erythromycin-resistant (MIC >1 μg/mL) iso-
lates were analyzed for the presence of erm(B), mef(A), and 
erm(TR) macrolide resistance genes by using a multiplex 
TaqMan PCR assay (16).
Results
Of 6,747 S. pneumoniae isolates collected at 119 cen-
ters in year 6 of PROTEKT US, 2,381 (35.3%) showed 
in vitro resistance to erythromycin; this result compares 
with 1,907/6,257 (30.5%) in year 5. Resistance rates for 
azithromycin and clarithromycin in year 6 were 35.3% and 
35.2%, respectively. Erythromycin resistance was stable at 
≈30% in years 3, 4, and 5. Analysis of isolates from centers 
common to years 3–6 showed a significantly higher rate for 
year 6 than for years 3–5 (p<0.0001 by χ2 test).
Erythromycin resistance varied considerably by geog-
raphy; the highest rates were in the North Central, South-
east, and South Central regions (Table 1). However, the 
rate of resistance increased from year 5 and year 6 in all 6 
regions (Table 1).
Erythromycin  resistance  increased  from  year  5  to 
year 6 in all patient age groups; the highest rates of re-
sistance occurred in isolates collected from children 0–2 
years of age (year 5: 423/882 [48.0%]; year 6: 533/1,058 
[50.4%]) (Figure 1).
Erythromycin resistance was less frequent in isolates 
collected from blood than in those collected from other 
sources  (487/1,801  [27.0%]  vs.  1,894/4,946  [38.3%]).
The proportion of erythromycin-resistant S. pneumoniae 
(ERSP) isolates exhibiting high-level resistance to eryth-
romycin (MIC >32 μg/mL) was 18.0% in year 6 compared 
with 13.4% in year 5.
Coresistance to penicillin (oral penicillin V for non-
meningitis isolates) was exhibited by 14.8% of ERSP iso-
lates collected in year 6 compared with 13.2% of ERSP iso-
lates collected at the same centers in year 5. Among all S. 
pneumoniae isolates, resistance to amoxicillin-clavulanate 
increased from 5.2% in year 5 to 8.1% in year 6; resistance 
to the third-generation oral cephalosporin, cefpodoxime, 
increased less substantially (19.4% in year 5 vs. 20.5% in 
year 6).
Genotyping
The distribution of genotypes among ERSP isolates 
changed from year 5 to year 6. Lower-level efflux mef(A)-
mediated macrolide resistance decreased, while high-level 
erm(B) with or without mef(A) increased (Table 2). In year 
6, just over half of ERSP isolates showed mef(A) resistance; 
nearly one quarter were positive for erm(B) and mef(A). 
Analysis of isolates from centers common to years 3–6 of 
the study indicated a significant decreasing prevalence of 
mef(A) and significantly increasing prevalence of erm(B) ± 
mef(A) (p<0.0001 and p = 0.0033, respectively, by χ2 test).
ERSP isolates from patients 0–2 years of age showed 
the highest frequency of the erm(B) + mef(A) genotype 
(38.6% in year 6 compared with 35.5% in year 5). With the 
exception of years 3–4, the proportion of isolates harbor-
ing erm(B) and mef(A) throughout the 6 years of the PRO-
TEKT US study has trended upward (Figure 2).
Most (398/575 [69.2 %]) of the erm(B) + mef(A) iso-
lates from year 6 were serotype 19A; most of the remainder 
(154/575 [26.8%]) were serotype 19F. Overall, 72.8% of 
year 6 ERSP isolates were susceptible to amoxicillin-cla-
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Table 1. Erythromycin resistance among Streptococcus pneumoniae isolates, year 5 (2004–2005) and year 6 (2005–2006) of the 
PROTEKT US surveillance study* 
Isolates,	no.	resistant/no.	submitted	(%)	
US region†  Year 5  Year 6 
Northeast 518/1,931	(26.8)	 662/2,102	(31.5)	
North	Central	 467/1,314	(35.5)	 568/1,395	(40.7)	
Northwest	 94/417	(22.5)	 108/422	(25.6)	
Southeast 340/998 (34.1)  419/1,064 (39.4) 
South Central  402/1,149	(35.0)	 529/1,368	(38.7)	
Southwest  86/448	(19.2)	 95/396	(24.0)	
Total 1,907/6,257	(30.5)	 2,381/6,747	(35.3)	
*PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States. 
†States submitting isolates for testing included	Northeast:	CT,	DE,	IN,	MA,	MD,	MI,	NJ,	NY,	OH,	PA,	RI,	VT,	and	DC;	North	Central:	IA,	IL,	KS,	MN,	MD,	
ND,	NE,	SD,	and	WI;	Northwest:	AK,	ID,	MT,	OR,	WA,	and	WY;	Southeast:	FL,	GA,	KY,	NC,	SC,	VA,	and	WV;	South	Central:	AL,	AR,	LA,	OK,	TN,	and	
TX;	Southwest:	AZ,	CA,	CO,	NM,	NV,	and	UT.		RESEARCH
vulanate. However, amoxicillin-clavulanate susceptibility 
varied considerably between genotypes; <10% of isolates 
carrying erm(B) and mef(A) genes were susceptible to this 
agent, compared with >90% of isolates harboring either 
gene alone (Table 3). MIC50 and MIC90 for amoxicillin-
clavulanate among erm(B) + mef(A) ERSP isolates were 
both >8 μg/mL; these were also the values for 19A and 19F 
strains. By contrast, >98% of ERSP isolates were suscep-
tible to levofloxacin and >99% were susceptible to telithro-
mycin. The genotypic mechanism of erythromycin resis-
tance had little impact on susceptibility to either of these 
agents (Table 3).
Discussion
These findings from PROTEKT US indicate that pneu-
mococcal macrolide resistance has demonstrated its first 
significant increase since the study began in 2000 (4,13,17). 
Whether the increase from ≈30% to 35% represents the 
start of a new upward trend will become evident only when 
results of surveillance studies in future years become avail-
able. However, it is worth noting that another smaller US 
surveillance study recently reported an azithromycin re-
sistance rate of 34% in S. pneumoniae isolates collected 
during the same 2005–2006 respiratory infection season as 
this analysis (18). A further sustained rise in macrolide re-
sistance would be a major cause for concern because mac-
rolides, such as azithromycin and clarithromycin, remain 
in widespread use for the treatment of community-acquired 
RTIs in the United States.
The increase in ERSP isolates from year 5 to year 6 in 
all 6 regions of the country indicates a lack of specific local 
factors that might explain this sudden increase. Even so, re-
sistance continued to be higher in some regions (Southeast, 
North Central, and South Central) than in others. Higher 
rates of macrolide resistance in the southern states aligns 
with a recent retrospective cohort study involving 1,574 
patients with pneumococcal bacteremia, which identified 
residence in the southern United States as a risk factor for 
infection with macrolide-nonsusceptible pneumococci (9).
Other potential explanations for the increase in mac-
rolide resistance include increased use and/or inappropriate 
prescription of macrolides. Pneumococcal macrolide resis-
tance in S. pneumoniae has been linked in several studies 
with increased consumption of macrolides in general and 
of azithromycin in particular (19). Other factors associated 
with pneumococcal macrolide resistance are recent use of 
antimicrobial drugs, age extremes, and daycare attendance 
(6,8). However, which (if any) of these factors might ex-
plain the trends reported here are not clear.
Another concern arising from this report is the con-
tinuing change in the distribution of macrolide-resistance 
genotypes. Although mef(A), usually associated with low-
er-level macrolide resistance, remains the most prevalent 
genotype, it now accounts for only about half of all ERSP 
isolates. Isolates carrying mef(A) continue to be replaced 
by strains that harbor mef(A) and erm(B) genes. Data from 
the first 4 years of PROTEKT US showed that the propor-
tion  of  S.  pneumoniae  isolates  positive  for  erm(B)  and 
mef(A) genes increased from 9.3% to 19.1% from Fall of 
2000 through spring of 2001 and the same for subsequent 
years through spring of 2004 while isolates positive for 
the mef(A) gene decreased over this time from 69.0% to 
60.7% (p = 0.03) (10). A Canadian study found a signifi-
cant increase of 8% (from 4% to 12%) in the prevalence 
of dual erm(B) and mef(A)-positive S. pneumoniae isolates 
(p<0.05)  between  Fall  and  spring  seasons  of  each  year 
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Figure 1. Increased prevalence of erythromycin-resistant Strepto-
coccus pneumoniae (ERSP), by age group, Prospective Resistant 
Organism Tracking and Epidemiology for the Ketolide Telithromycin, 
United States surveillance study, years 1–6 (2000–2006).
Table 2. Macrolide resistance genotypes, year 5 (2004-2005) and year 6 (2005–2006) of the PROTEKT US surveillance study* 
No.	isolates	(%	of	ERSP)†	
Genotype  Year 5 (n = 1,907)  Year 6 (n = 2,381) 
erm(B) 310 (16.3)  448 (18.8) 
mef(A) 1,172 (61.5)  1,282 (53.8) 
erm(B) + mef(A)  377 (19.8)  575 (24.1) 
erm(TR)  2 (0.1) 0
Ribosomal mutations  26 (1.4)  41 (1.7) 
*PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; ERSP, erythromycin-resistant 
Streptococcus pneumoniae.
†A total of 20 isolates in year 5 and 35 isolates in year 6 were not viable for genotyping. Pneumococcus Macrolide Resistance, United States
(1998–2004); this increase coincided with a 17% decrease 
in high-level erm(B)-mediated resistance and a 5% increase 
in the proportion of isolates carrying only the mef(A) gene 
(20). The latest PROTEKT US data show that these trends 
are continuing; nearly one quarter of year 6 ERSP isolates 
have both resistance genes, and the frequency of this geno-
type is approaching 40% in isolates from children.
The increased prevalence of isolates harboring erm(B) 
and mef(A) genes is most likely due to the recent expansion 
in the US and elsewhere of a multidrug-resistant serotype 
19A pneumococcal clone that carries both resistance genes 
(21,22). The expansion of this clonal variant resistance pro-
vides at least a partial explanation for the greater frequency 
of high-level erythromycin resistance observed in year 6 
compared with that of the previous year. Most erm(B) + 
mef(A)  strains  show  high-level  resistance  to  macrolides 
(MIC >32 μg/mL). In addition, although mef(A) is tradi-
tionally associated with lower-level macrolide resistance 
(MIC 1–4 μg/mL), recent data suggest that the macrolide 
MICs for a growing proportion of mef(A) isolates exceed 
16 μg/mL (10).
Because most erm(B) + mef(A) strains show multidrug 
resistance (21), their increased prevalence may compromise 
the effectiveness of other commonly used antimicrobial ther-
apies. For example, although >90% of all S. pneumoniae iso-
lates collected in year 6 of PROTEKT US exhibited in vitro 
susceptibility to amoxicillin-clavulanate, <10% of erm(B) + 
mef(A) isolates tested in this analysis were susceptible to this 
agent. Moreover, the MIC distribution for amoxicillin-clavu-
lanate within the erm(B) + mef(A) isolates (MIC50 and MIC90 
both >8 μg/mL) suggests that no oral β-lactam antimicrobial 
drug may be available that can provide adequate concentra-
tions to eradicate these increasingly prevalent strains. On the 
other hand, the fluoroquinolone levofloxacin and the ketolide 
telithromycin continue to show good activity against ERSP 
isolates, with little impact of resistance genotype on their re-
spective activities.
Our study is subject to several potential limitations. 
A major potential limitation inherent in surveillance stud-
ies that measure in vitro antimicrobial drug resistance is 
their clinical relevance. Although an association between 
in vitro resistance and adverse clinical outcome remains 
generally  unproven  for  most  respiratory  infections,  an 
increasing number of studies indicate that infection with 
macrolide-resistant pneumococci is associated with clinical 
failure (6–9,22). Furthermore, clinical failures have been 
associated with mef(A)- and erm(B)-mediated resistance 
(6,23,24). A second potential limitation of this study is the 
derivation of resistance rates from collection centers where 
a predetermined number of isolates were to be collected 
and may not entirely reflect those found more widely.
These data from PROTEKT US year 6 indicate that 
in vitro pneumococcal macrolide resistance may not have 
plateaued as previously thought. Continued surveillance of 
erythromycin resistance in general, and of highly resistant 
erm(B) + mef(A) strains in particular, is warranted.
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Figure 2. Increased prevalence in the erm(B) + mef(A) macrolide 
resistance genotype from year 1 (2000–2001) to year 6 (2005−2006), 
Prospective Resistant Organism Tracking and Epidemiology for the 
Ketolide Telithromycin, United States surveillance study.
Table 3. Antimicrobial susceptibility of erythromycin-resistant isolates, by genotype, year 6 (2005–2006) of the PROTEKT US 
surveillance study* 
Amoxicillinclavulanate  Levofloxacin  Telithromycin 
Susceptibility, %  MIC, ȝg/mL  Susceptibility, % MIC, ȝg/mL  Susceptibility, %  MIC, ȝg/mL 
Genotype  S  I  R    MIC50  MIC90 S  I  R  MIC50 MIC90 S  I  R    MIC50 MIC90
erm(B)†  96.2  0.9  2.9    0.12  2  98.2 0.2 1.6 1  1  99.1  0.7  0.2    0.03  0.12 
mef(A)‡  92.1  3.7  4.2    0.25  2  98.9 0.1 1.0 1  1  99.6  0.4  0    0.25  0.5 
erm(B) + mef(A)§  9.7  9.9  80.3   > 8  >8  98.8 0.2 1.0 1  1  99.1  0.5  0.3   1   1 
*PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; S, susceptible; I, intermediate; 
R, resistant. 
†n = 448. 
‡n = 1,282. 
§n = 575. RESEARCH
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